Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

160Citations
Citations of this article
126Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Natalizumab, a humanized monoclonal IgG4 antibody to αA integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied. Methods: Seventy-nine adult patients with active CD (Crohn's Disease Activity Index [CDAI] score ≥ 150) despite ongoing infliximab treatment were randomized 2:1 to receive 3 intravenous infusions of natalizumab (300 mg; n = 52) or placebo (n = 27) every 4 weeks. Patients received infliximab (5 mg/kg) every 8 weeks for at least 10 weeks before randomization and throughout the study. The primary objective was to assess the short-term safety and tolerability of natalizumab in patients concurrently receiving infliximab. Secondary and tertiary objectives included measures of efficacy, health-related quality of life (HRQoL), and effects on inflammatory markers. A subset of patients also participated in a pharmacokinetic/ pharmacodynamic (PK/PD) analysis of the effects of concurrent treatment. Results: Incidence of adverse events (AEs) was similar in the treatment groups. AEs frequently reported in both groups were headache, CD exacerbation, nausea, and nasopharyngitis. No patient had a hypersensitivity-like reaction to natalizumab, whereas 4 patients (5%) experienced reactions to infliximab. Two patients (4%) developed anti-natalizumab antibodies; 10 patients (14%) developed anti-infliximab antibodies. The mean CDAI score decreased with natalizumab plus infliximab but was unchanged with infliximab alone (-37.7 versus +3.5; P = 0.084). Patients in both groups showed small increases in HRQoL (P = 0.811). No drug-drug interactions were noted. Conclusions: The combination of natalizumab plus infliximab was well tolerated. Several positive trends suggested that treating patients not in remission with infliximab plus natalizumab had greater efficacy than treatment with infliximab alone. Copyright © 2006 Crohn's & Colitis Foundation of America, Inc.

References Powered by Scopus

Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial

3920Citations
N/AReaders
Get full text

Inflammatory bowel disease

3327Citations
N/AReaders
Get full text

Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study

3286Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Management of Crohn's disease in adults

796Citations
N/AReaders
Get full text

Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis

547Citations
N/AReaders
Get full text

Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis

314Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sands, B. E., Kozarek, R., Spainhour, J., Barish, C. F., Becker, S., Goldberg, L., … Hanauer, S. B. (2007). Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflammatory Bowel Diseases, 13(1), 2–11. https://doi.org/10.1002/ibd.20014

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 32

57%

Researcher 16

29%

Professor / Associate Prof. 8

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 61

84%

Pharmacology, Toxicology and Pharmaceut... 4

5%

Agricultural and Biological Sciences 4

5%

Psychology 4

5%

Save time finding and organizing research with Mendeley

Sign up for free